Cargando…

Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer

Pancreatic cancer is difficult to diagnose at the initial stage and is often discovered after metastasis to nearby organs. Gemcitabine is currently used as a standard treatment for pancreatic cancer. However, since chemotherapy for pancreatic cancer has not yet reached satisfactory therapeutic resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koh, Eun-Kyoung, Lee, Hong-Rae, Son, Woo-Chang, Park, Ga-Young, Kim, Juhee, Bae, Jae-Ho, Park, You-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175562/ https://www.ncbi.nlm.nih.gov/pubmed/37169953 http://dx.doi.org/10.1038/s41598-023-34827-z

Ejemplares similares

Antitumor effects of NK cells expanded by activation pre‑processing of autologous feeder cells before irradiation in colorectal cancer
por: Koh, Eun-Kyoung, et al.
Publicado: (2023)

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma
por: Messaoudene, Meriem, et al.
Publicado: (2014)

Autologous cellular therapy for myeloma: Giving ex vivo expanded NK cells their due
por: Shapiro, Roman M., et al.
Publicado: (2022)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy
por: Matsui, Hiroto, et al.
Publicado: (2017)

Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma
por: Rodríguez-Nogales, Carlos, et al.
Publicado: (2020)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects
por: Wang, Xiao, et al.
Publicado: (2022)

Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells
por: Vahedi, Fatemeh, et al.
Publicado: (2017)

Radiation-induction of MMPs limited the NK-mediated anticancer immunity in lung cancer cells
por: Heo, Woong, et al.
Publicado: (2014)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells
por: Cho, Haeryung, et al.
Publicado: (2021)

Combinatorial Immunotherapies for Metastatic Colorectal Cancer
por: Janssen, Eline, et al.
Publicado: (2020)

Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of Gemcitabine
por: Clouser, Christine L., et al.
Publicado: (2011)

Combinatorial Effect of Prophylactic Interventions for Post-ERCP Pancreatitis among Patients with Risk Factors: A Network Meta-Analysis
por: Choi, Jin Ho, et al.
Publicado: (2023)

Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells
por: Son, Cheol-Hun, et al.
Publicado: (2016)

Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody
por: Lee, Hong-Rae, et al.
Publicado: (2017)

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas
por: Pan, Changqing, et al.
Publicado: (2021)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Neuroprotective effects of ex vivo-expanded regulatory T cells on trimethyltin-induced neurodegeneration in mice
por: Park, Seon-Young, et al.
Publicado: (2022)

“Adherent” versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy
por: Selvan, Senthamil R., et al.
Publicado: (2015)

Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam
por: Liem, Nguyen Thanh, et al.
Publicado: (2019)

Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19
por: Ahmadvand, Mohammad, et al.
Publicado: (2023)

Upregulation of Myc promotes the evasion of NK cell-mediated immunity through suppression of NKG2D ligands in K562 cells
por: Lee, Young-Shin, et al.
Publicado: (2019)

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
por: Michalski, C W, et al.
Publicado: (2008)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

NK Cell-Based Immunotherapies in Cancer
por: Shin, Min Hwa, et al.
Publicado: (2020)

NK cell-based tumor immunotherapy
por: Zhang, Hao, et al.
Publicado: (2023)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017)

Effective combinatorial immunotherapy for penile squamous cell carcinoma
por: Huang, Tianhe, et al.
Publicado: (2020)

Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
por: Chun, Jung Won, et al.
Publicado: (2021)

Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Liu, Yanfeng, et al.
Publicado: (2022)

Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
por: Cho, Jae Hee, et al.
Publicado: (2017)

Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
por: Lee, Jeung Eun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b4e4nsgkhcsjhpgiq1qgqcnqk6